fexofenadine has been researched along with Electrocardiogram QT Prolonged in 9 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arsenic trioxide (As2O3) has been verified as a breakthrough in the management of acute promyelocytic leukemia in recent decades." | 3.85 | Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism. ( Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M, 2017) |
| "The long QT syndrome is a rare disease." | 1.33 | Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Yan, M | 1 |
| Feng, L | 1 |
| Shi, Y | 1 |
| Wang, J | 1 |
| Liu, Y | 1 |
| Li, F | 1 |
| Li, B | 1 |
| Couderc, JP | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Moneret-Vautrin, DA | 1 |
| de Chillou, C | 1 |
| Codreanu, A | 1 |
| Pinto, YM | 1 |
| van Gelder, IC | 1 |
| Heeringa, M | 1 |
| Crijns, HJ | 1 |
| Shuster, J | 1 |
| Dhar, S | 1 |
| Hazra, PK | 1 |
| Malakar, S | 1 |
| Mistri, G | 1 |
| Rajamani, S | 1 |
| Anderson, CL | 1 |
| Anson, BD | 1 |
| January, CT | 1 |
1 review available for fexofenadine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
8 other studies available for fexofenadine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK2 | 2017 |
QT interval prolongation and beyond.
Topics: Animals; Anti-Allergic Agents; Dogs; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Terf | 2006 |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct | 2006 |
QT lengthening and life-threatening arrhythmias associated with fexofenadine.
Topics: Aged; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Syncope; Tachyc | 1999 |
Fexofenadine and prolonged QT intervals.
Topics: Aged; Drug Monitoring; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male | 1999 |
Fexofenadine-induced QT prolongation: a myth or fact?
Topics: Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenadine | 2000 |
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Topics: Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Electric Conductivity; ERG1 Pot | 2002 |